APA (7th ed.) Citation

Forner, S., Sim, V. R., Glendenning, J. L., & Burcombe, R. (2018). 223PThe impact of neoadjuvant dual HER2 targeting with pertuzumab and trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience. Annals of Oncology, 29, N.PAG. https://doi.org/10.1093/annonc/mdy270.218

Chicago Style (17th ed.) Citation

Forner, S., V R. Sim, J L. Glendenning, and R. Burcombe. "223PThe Impact of Neoadjuvant Dual HER2 Targeting with Pertuzumab and Trastuzumab on Pathological Complete Response (pCR) Rates: Kent Oncology Centre (KOC) Experience." Annals of Oncology 29 (2018): N.PAG. https://doi.org/10.1093/annonc/mdy270.218.

MLA (9th ed.) Citation

Forner, S., et al. "223PThe Impact of Neoadjuvant Dual HER2 Targeting with Pertuzumab and Trastuzumab on Pathological Complete Response (pCR) Rates: Kent Oncology Centre (KOC) Experience." Annals of Oncology, vol. 29, 2018, p. N.PAG, https://doi.org/10.1093/annonc/mdy270.218.